About ExstoBio

Developing the future of personalized cannabinoid therapeutics.

ExstoBio provides confidence and precision through our science-based, data-driven approach.


01. History of Cannabis-as-a-Medicine

Cannabis is a plant with a long and colorful history. It has origins tracing back to the ancient world with evidence suggesting its use more than 5,000 years ago in what is now Romania. As far back as 2800 BC, cannabis was used to treat a vast array of health problems. From there, it was used as a patent medicine during the 19th and early 20th centuries, as described in the United States Pharmacopoeia for the first time in 1850.

In 1942, subsequent to the Act of 1937, cannabis was officially dropped from the United States Pharmacopoeia. Beyond criminalization, these legislative actions contributed to creating limitations on scientific research by restricting procurement of cannabis for academic and research institutions.

In 1996 California became the first state to legally allow doctors to prescribe cannabis for medical purposes. In 2012, CBD—the non-psychoactive compound in cannabis that is believed to have a number of health benefits—was shown to alleviate symptoms of schizophrenia in patients comparable to a conventional antipsychotic drug. In 2016, Australia legalised medical cannabis and its cultivation for medicinal purposes, and in 2017, CBD was demonstrated to reduce seizures in childhood epilepsy in a placebo-controlled trial.

However, in December 2022, the United States Congress passed the Medical Marijuana and Cannabidiol Research Act which opens the door to scientific research and restores the patient-physician relationship.

02. Current State of the Market

The global cannabis pharmaceutical market size was valued at USD 943.5 million in 2021. Over the next few years, cannabis therapeutics is projected to expand at a Compound Annual Growth Rate (CAGR) of 101.7%.

The global market for cannabis therapeutics is also experiencing rapid expansion. For instance, medical cannabis is legal in countries such as Australia, Barbados, Canada, Chile, Colombia, Costa Rica, Cyprus, Czech Republic, Denmark, Finland, Poland, Portugal, and the United Kingdom among others.

03. The Benefits of Medicinal Cannabis

In 1999, the National Academies of Sciences, Engineering, and Medicine supported the use of cannabis-as-a-medicine. With a science-based, data-driven approach, ExstoBio is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates.

Through R&D and planned clinical trials, ExstoBio is committed to furthering the understanding of cannabinoids with the development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations.

Additionally, ExstoBio is dedicated to delivering high quality, cGMP-compliant cannabinoid products that you can trust. ExstoBio is elevating cannabinoid-based therapeutics as the standard of care  in pursuit of a transformational impact on patients’ lives around the world.

"I think that [ExstoBio's approach] is probably the future of this whole industry."

Dr. Loc Thang, M.D., Ph.D. Washington University in St. Louis


Industry CAGR


of patients find cannabis therapeutics much more effective compared to their prescription drugs


of patients reported a substantial decrease in prescription drug use when offered medical cannabis as a substitute for prescription drugs


is lost across the pharmaceutical industry each time a U.S. state legalizes medical cannabis

The ExstoBio Difference

Product Safety & Integrity

Over 75% of cannabidiol products are mislabeled and many contain heavy metals. Patients deserve to know and trust what is in their treatment.

Rooted in science and crafted under the highest standards, ExstoBio cannabinoid therapeutics are developed with the patient in mind.

Science-based, Data-driven.

Leading with scientific research and a thorough dedication to data, ExstoBio is disrupting the pharmaceutical industry, formalizing cannabis-as-a-medicine, and personalizing patient care.

Supervised medical cannabis treatment is associated with high-adherence, improvement in QoL, and decrease in pain levels with a low incidence of serious adverse events.

Harm Reduction Journal, 2019. Phillipe Lucas, Eric P. Baron, & Nick Jikomes.

Get helpful, doctor-recommended medical cannabis news and tips delivered to your inbox.

* We respect your privacy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Get useful insight from our team.

* Small disclaimer here about grabbing that sweet data.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.